Finance

Lists
Why is AKUMS down 2,51%?
Dive Deeper
AKUMS:NSE
Akums Drugs and Pharmaceuticals Ltd
731,00 ₹
-2,51%
(-18,80) 1D
16 қаз., 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for AKUMS...
Open
749,80 ₹
High
752,80 ₹
Low
728,70 ₹
Mkt. cap
111,92 млрд
Avg. vol.
272,03 м.
Volume
150,74 м.
Dividend
0,14%
Quarterly dividend
0,25 ₹
Ex-dividend date
2026 ж. 03 шіл.
P/E ratio
38,38
52-wk high
838,80 ₹
52-wk low
409,30 ₹
EPS
19,05 ₹
No. of employees
7 мың
Open
749,80 ₹
High
752,80 ₹
Low
728,70 ₹
Mkt. cap
111,92 млрд
Avg. vol.
272,03 м.
Volume
150,74 м.
Dividend
0,14%
Quarterly dividend
0,25 ₹
Ex-dividend date
2026 ж. 03 шіл.
P/E ratio
38,38
52-wk high
838,80 ₹
52-wk low
409,30 ₹
EPS
19,05 ₹
No. of employees
7 мың
News stories
From web sources and news partners
Profile
Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical Contract Development and Manufacturing Organization that serves both domestic and multinational pharmaceutical companies. The company was established in 2004 and became publicly listed on 6 August 2024. Wikipedia
About Akums Drugs and Pharmaceuticals Ltd
CEO-
Employees7,34 мың
Founded2004
Headquarters-
Sector-
Websiteakums.in
Last report
2026 ж. 10 там.
Fiscal period
Q1 2027
6,53 ₹ / 6,10 ₹
+7,05%beat
Revenue / Est. (INR)
11,67 млрд / 11,65 млрд
+0,14%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
10,18 млрд
11,60 млрд
11,60 млрд
11,67 млрд
Cost of goods sold
5,93 млрд
6,79 млрд
7,37 млрд
6,45 млрд
Cost of revenue
5,93 млрд
6,79 млрд
7,37 млрд
6,45 млрд
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,89 млрд
1,89 млрд
2,37 млрд
2,01 млрд
Operating expense
3,68 млрд
3,74 млрд
3,09 млрд
3,88 млрд
Total operating expenses
9,61 млрд
10,52 млрд
10,46 млрд
10,33 млрд
Operating income
566,12 млн
1,07 млрд
1,14 млрд
1,34 млрд
Other non operating income
323,65 млн
343,28 млн
-942,12 млн
303,80 млн
EBT including unusual items
656,73 млн
995,66 млн
1,21 млрд
1,39 млрд
EBT excluding unusual items
656,73 млн
1,18 млрд
1,19 млрд
1,39 млрд
Income tax expense
229,77 млн
318,92 млн
398,74 млн
382,59 млн
Effective tax rate
34,99%
32,03%
32,89%
27,48%
Other operating expenses
1,41 млрд
1,45 млрд
319,86 млн
1,45 млрд
Net income
407,83 млн
663,17 млн
846,13 млн
1,00 млрд
Net profit margin
4,01%
5,72%
7,29%
8,57%
Earnings per share
2,66
5,14
-
6,53
Interest and investment income
-
-
1,10 млрд
-
Interest expense
-233,04 млн
-237,42 млн
-184,41 млн
-247,56 млн
Net interest expenses
-233,04 млн
-237,42 млн
912,36 млн
-247,56 млн
Depreciation and amortization charges
378,64 млн
396,49 млн
401,18 млн
410,65 млн
EBITDA
940,04 млн
1,42 млрд
1,49 млрд
1,69 млрд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google қолданбалары